Evaluation of the Clinical Utility of Plasma Biomarkers in Diagnosis of Neuroendocrine Tumors
#899
Introduction: Neuroendocrine tumors (NETs) are rare cancers that usually develop in the gastroenterohepatic system. Diagnostic workup of these tumors includes measurement of plasma levels of marker peptides. Clinical experience suggests that these markers may be misleading if used before histological or imaging evidence of a NET is available.
Aim(s): This study explored the clinical utility of chromogranin A (CgA), neurokinin A (NKA) and pancreatic polypeptide (PP) in the diagnosis of NETs.
Materials and methods: Computer searches of hospital records were used to gather data on the initial results of all requests for CgA, NKA, and PP received by the department of biochemistry from 01/2010 to 12/2012 from any source. The clinical records were received and relevant data extracted for analysis. Patients with elevated biomarkers were classified as false positive by biopsy or if imaging and review of the case by a consultant led to the conclusion that the symptoms had an alternative aetiology. Biomarkers were measured in 99 patients (58 female, mean age 59, SD 15).
Conference: 11th Annual ENETSConcerence (2014)
Presenting Author: Lunberg-Adams M
Authors: Lunberg-Adams M, James A, Perros P,
Keywords: chromogranin A, neurokinin A, pancreatic polypeptide, neuroendocrine tumor diagnosis,
To read the full abstract, please log into your ENETS Member account.